BMC CancerCancer BiologyPeer-reviewed journal article
Integrated multi-omics profiling uncovers the epigenetic, transcriptional, and metabolic landscape of prostate cancer progression
Christine Aaserød PederseniD, Maximilian WessiD, Maria K. AnderseniD, Elise MidtbustiD, Abhibhav SharmaiD, Thomas FleischeriD, Morten Beck RyeiD, May‐Britt TessemiD
Abstract
A comprehensive understanding of the underlying molecular mechanisms of prostate cancer is essential for the development of precise diagnostic biomarkers. In this study, we applied unsupervised multi-omics factor analysis (MOFA) to integrate DNA methylation, gene expression, and metabolic profiles derived from the same individuals, aiming to characterize the biological landscape of normal, malignant, and aggressive prostate tissue. Our analysis identified distinct molecular pathways associated with aggressive disease, specifically those involved in zinc metabolism, cell cycle regulation, smooth muscle architecture, immune activation, and tissue morphology. Key metabolites within the TCA cycle, amino acid metabolism, and lipid pathways were central to these signatures. Furthermore, we observed a consistent co-enrichment of SP1 and CTCFL binding regions among factor-associated CpGs, suggesting a model of global epigenetic reprogramming. These findings indicate a novel interplay between Polycomb deregulation, CTCFL-mediated chromatin remodeling, and SP1-driven transcriptional activation in shaping the prostate cancer epigenome. Apart from immune activation, the identified molecular signatures were validated in the TCGA cohort and demonstrated significant predictive value for disease recurrence. Overall, these results underscore the power of multi-omics integration in providing a holistic understanding of prostate cancer biology and its potential for clinical translation into prognostic biomarkers.
- organism: human
- assay: DNA methylation
- assay: bulk RNA-seq
- assay: metabolomics
- research focus: gene regulatory network inference
- research focus: differential expression
- research focus: protein structure prediction
- research focus: drug response / drug discovery
- approach: statistical model
- Citations
- 1
- FWCI
- 4.71
- Field percentile
- top 6%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Multi-omics biomarkers aid prostate cancer prognostication
Zhuoran Xu, Mohamed Omar, … Luigi Marchionni·bioRxiv·Sep 20, 2022
- Multi-omics data integration approach identifies potential biomarkers for Prostate cancer
Zedias Chikwambi, Marie Hidjo, … David Enoma·bioRxiv·Jan 26, 2023
- The Landscape of Prostate Tumour Methylation
Jaron Arbet, Takafumi N. Yamaguchi, … Paul Christopher Boutros·Cancer DiscoveryPeer-reviewed·Jun 17, 2026
- Identification of Biomarkers and Trajectories of Prostate Cancer Progression: A Bioinformatics Fusion of Weighted Correlation Network Analysis and Machine Learning
Raheleh Sheibani‐Tezerji, Carlos Uziel Pérez Malla, … Gerda Egger·bioRxiv·Mar 2, 2023
- Novel Methylation Markers in a Prostate Cancer Cohort are Associated with Disease Development and Relapse
R. P. Lach, S. Pita, … A. G. Lynch·bioRxiv·Aug 27, 2026
- Deep phenotyping of the prostate tumor microenvironment reveals molecular stratifiers of relapse and links inflammatory chemokine expression to aberrant metabolism
Sebastian Krossa, Maria K. Andersen, … May‐Britt Tessem·Nature CommunicationsPeer-reviewed·Nov 19, 2025